Is There a Future for Histone Deacetylase Inhibitors in the Pharmacotherapy of Psychiatric Disorders?

  title={Is There a Future for Histone Deacetylase Inhibitors in the Pharmacotherapy of Psychiatric Disorders?},
  author={Dennis R. Grayson and Marija Kundakovic and Rajiv P. Sharma},
  journal={Molecular Pharmacology},
  pages={126 - 135}
In recent years, it has become widely recognized that a comprehensive understanding of chromatin biology is necessary to better appreciate its role in a wide range of diseases. The histone code has developed as a new layer of our appreciation of transcription factor-based mechanisms of gene expression. Although epigenetic regulation refers to a host of chromatin modifications that occur at the level of DNA, histones, and histone-associated proteins, how this regulation is orchestrated is still… 

Figures and Tables from this paper

Histone deacetylase inhibitors: pharmacotherapeutic implications as epigenetic modifier

Histone Deacetylase Inhibitors (HDACIs) have potential to restore the balance of histone acetylation that reverses the silencing of pathological genes and act as epigenetic modifiers.

Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis.

The present article reviews the recent findings on the role played by HDACs and the possible function of different histone modifications in epilepsy and epileptogenesis and indicates HDACIs as potential new therapeutic agents for the treatment of human epilepsy.

HDAC inhibitor‐based therapies: Can we interpret the code?

Epigenetic modulation: Research progress on histone acetylation levels in major depressive disorders.

This review explores the relationship between HDACs and depression and focuses on the current knowledge on their regulatory mechanism in depression and the potential therapeutic use of HDACis with antidepressant efficacy in preclinical research.

Small Molecule Inhibitors of Zinc-dependent Histone Deacetylases

Continued development and characterization of highly optimized small molecule inhibitors of HDAC enzymes will help refine the understanding of their function and, optimistically, lead to novel therapeutic treatment alternatives for a host of neurological disorders.

Targeting specific HATs for neurodegenerative disease treatment: translating basic biology to therapeutic possibilities

This review focuses on the recent progress in research regarding epigenetic histone acetylation mechanisms underlying neuronal activity and cognitive function, and the current understanding of specific HDACs and HATs in neurodegenerative diseases and the future promising prospects of using specific HAT based therapeutic approaches.



Histone deacetylase inhibitors: Understanding a new wave of anticancer agents

The current data indicate that the use of HDAC inhibitors, probably in association with classical chemotherapy drugs or in combination with DNA‐demethylating agents, could be promising for cancer patients.

Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review

This review is an effort to summarize the nonclinical and clinical status of HDAC inhibitors currently under development in anticancer therapy.

Epigenetic Therapeutic Strategies for the Treatment of Neuropsychiatric Disorders: Ready for Prime Time?

The epigenetic therapeutic strategy has much promise, and its development will foster collaboration and cross fertilization between molecular and cell biologists, oncologists, psychiatrists, and neurologists.

MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent.

Targeting histone deacetylase in cancer therapy

An overview of the use of HDAC inhibitors in cancer treatment is provided and the physiological relevance ofHDAC‐mediated acetylation of histone and nonhistone substrates is addressed, the chemical biology of HD ACs and development of a novel class of HDac inhibitors, and the protein acetylations‐independent effect of HDacellular kinases on the activation status of signaling kinases are addressed.

Histone deacetylases: target enzymes for cancer therapy

A comprehensive overview of the role and the involvement of HDAC in carcinogenesis as well as the current progress on the development ofHDAC general and specific inhibitors as new cancer therapies is given.

Anticancer activities of histone deacetylase inhibitors

Recent advances in the understanding of the molecular events that underlie the anticancer effects of HDAC inhibitors are summarized and how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs are discussed.

Histone deacetylases (HDACs): characterization of the classical HDAC family.

The aim of this review is to give a comprehensive overview of the structure, function and tissue distribution of members of the classical histone deacetylase (HDAC) family, in order to gain insight into the regulation of gene expression through HDAC activity.

Biomarkers for predicting clinical responses to HDAC inhibitors.